Literature DB >> 7675843

Dopaminergic drugs in the medial preoptic area and nucleus accumbens: effects on motor activity, sexual motivation, and sexual performance.

J Moses1, J A Loucks, H L Watson, L Matuszewich, E M Hull.   

Abstract

In two experiments, dopamine agonists and/or antagonists were injected into the medial preoptic area (MPOA) or the nucleus accumbens (NAcc) of male rats. The animals were then tested in an X-mase with four goal boxes, which contained a receptive female, a male, or were empty. In Experiment 1, the D1 antagonist SCH-23390 and the D2 antagonist raclopride in the MPOA decreased the percentage of trials on which the female's chamber was chosen, a measure of sexual motivation. Raclopride also decreased the number of animals that copulated after choosing the female's chamber. The 10-micrograms dose of the D3/D2 agonist quinelorane increased the latency to reach the female's chamber, slowed the onset of copulation, and decreased the number of intromissions preceding an ejaculation. In Experiment 2, 1- and 5-micrograms doses of quinelorane and of the mixed D1/D2 agonist apomorphine were injected bilaterally into the NAcc. Both doses of quinelorane increased the number of times that the subject did not select a chamber within 60 s. No drug in the NAcc affected specifically sexual motivation or performance. The results are consistent with differential influence of the MPOA and the NAcc on motor activity, sexual motivation, and sexual performance.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7675843     DOI: 10.1016/0091-3057(94)00437-n

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  17 in total

1.  Some rewarding effects of androgens may be mediated by actions of its 5alpha-reduced metabolite 3alpha-androstanediol.

Authors:  Cheryl A Frye
Journal:  Pharmacol Biochem Behav       Date:  2006-11-15       Impact factor: 3.533

2.  Nucleus accumbens dopamine increases sexual motivation in sexually satiated male rats.

Authors:  Irma Lorena Guadarrama-Bazante; Gabriela Rodríguez-Manzo
Journal:  Psychopharmacology (Berl)       Date:  2018-12-08       Impact factor: 4.530

3.  Effects of morphiceptin in the medial preoptic area on male sexual behavior.

Authors:  L Matuszewich; J L Ormsby; J Moses; D S Lorrain; E M Hull
Journal:  Psychopharmacology (Berl)       Date:  1995-12       Impact factor: 4.530

4.  Dopamine D1 receptors and phosphorylation of dopamine- and cyclic AMP-regulated phosphoprotein-32 in the medial preoptic area are involved in experience-induced enhancement of male sexual behavior in rats.

Authors:  Jenna A McHenry; Genevieve A Bell; Bradley P Parrish; Elaine M Hull
Journal:  Behav Neurosci       Date:  2012-06-18       Impact factor: 1.912

Review 5.  Evidence for opioid involvement in the motivation to sing.

Authors:  Lauren V Riters
Journal:  J Chem Neuroanat       Date:  2009-04-05       Impact factor: 3.052

Review 6.  Post-finasteride syndrome and post-SSRI sexual dysfunction: two sides of the same coin?

Authors:  Silvia Giatti; Silvia Diviccaro; Giancarlo Panzica; Roberto Cosimo Melcangi
Journal:  Endocrine       Date:  2018-04-19       Impact factor: 3.633

Review 7.  Pleasure seeking and birdsong.

Authors:  Lauren V Riters
Journal:  Neurosci Biobehav Rev       Date:  2011-01-18       Impact factor: 8.989

8.  D1-like dopamine receptor density in nuclei involved in social behavior correlates with song in a context-dependent fashion in male European starlings.

Authors:  S A Heimovics; C A Cornil; G F Ball; L V Riters
Journal:  Neuroscience       Date:  2009-01-27       Impact factor: 3.590

9.  Dopamine mediates testosterone-induced social reward in male Syrian hamsters.

Authors:  Margaret R Bell; Cheryl L Sisk
Journal:  Endocrinology       Date:  2013-01-31       Impact factor: 4.736

10.  Evidence that dopamine within motivation and song control brain regions regulates birdsong context-dependently.

Authors:  Sarah A Heimovics; Lauren V Riters
Journal:  Physiol Behav       Date:  2008-06-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.